Jessica Hou

Ms. Hou is actively involved in MGP’s investments and currently serves on the board of Colorescience and KFx Medical and as a board observer at TigerConnect. She also works closely with other MGP portfolio companies, including Crown Laboratories. She had also represented Montreux on the board of SI-BONE (NASDAQ: SIBN) and had managed Montreux’s investment in Tobira Therapeutics (NASDAQ: TBRA, acquired by Allergan).
Previously, she was at Quaker Partners, a healthcare investment firm, where she evaluated and executed investments in biopharmaceutical, medical device, diagnostics, healthcare services, and consumer healthcare companies. Prior to joining Quaker, Ms. Hou was a Managing Consultant at Navigant Consulting, where she led and conducted numerous projects in commercial strategy and business development advisory for healthcare clients, including large-cap and specialty pharmaceutical, biotechnology, and healthcare services companies. Ms. Hou also worked in marketing at Abbott on the global launch of its bioresorbable stent. She has contributed to policy and research initiatives supporting regulatory reform with the Medical Innovation and Competitiveness (MedIC) Coalition and National Venture Capital Association (NVCA).
Ms. Hou earned an M.B.A. from Stanford Graduate School of Business and a B.A. in Human Biology and English from Stanford University.